NEW YORK, April 23 -- Affymetrix had a net loss of $12.7 million on revenues of $66.8 million as it reported first-quarter 2003 earnings today. The loss ended a run of two straight quarters of profitability.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.